secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2026-08-14T13:36:58+00:00
Accession:  0001628280-26-056966
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 3.02, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience to acquire Redx Pharma; Redx holders to own ~46% of combined company
--------------------------------------------------------------------------------

- Skye to acquire Redx Pharma via UK scheme of arrangement; Redx valued at $125M, Skye at $14.5M.
- Post-close ownership: Redx shareholders ~46.17%, Skye ~5.38%, new investors ~48.45% (assuming $67.9M concurrent financing).
- Concurrent financing of $67.9M (up to $72.9M) plus $5M side letter and $22M equity line; warrant valued at $5M.
- Redx management to lead combined company: Lisa Anson CEO, Peter Collum CFO; current Skye executives and board to resign.
- Shareholders to receive CVRs: Skye legacy CVR (90% of net proceeds from certain assets) and Redx CVR (100% of Redx asset proceeds).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/0001628280-26-056966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-056966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer